MX2013014577A - Compuestos de heteroarilo como ligandos del receptor 5-ht4. - Google Patents

Compuestos de heteroarilo como ligandos del receptor 5-ht4.

Info

Publication number
MX2013014577A
MX2013014577A MX2013014577A MX2013014577A MX2013014577A MX 2013014577 A MX2013014577 A MX 2013014577A MX 2013014577 A MX2013014577 A MX 2013014577A MX 2013014577 A MX2013014577 A MX 2013014577A MX 2013014577 A MX2013014577 A MX 2013014577A
Authority
MX
Mexico
Prior art keywords
receptor ligands
heteroaryl compounds
compounds
formula
pharmaceutically acceptable
Prior art date
Application number
MX2013014577A
Other languages
English (en)
Other versions
MX337721B (es
Inventor
Venkateswarlu Jasti
Ramakrishna Nirogi
Gopinadh Bhyrapuneni
Abdul Rasheed Mohammed
Anil Karbhari Shinde
Jyothsna Ravula
Sriramachandra Murthy Patnala
Ramasastri Kambhampati
Suresh Yarlagadda
Srinivasa Rao Ravella
Praveen Kumar Roayapalley
Pradeep Jayarajan
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2013014577A publication Critical patent/MX2013014577A/es
Publication of MX337721B publication Critical patent/MX337721B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

La presente invención se relaciona con compuestos novedosos de fórmula (I) y sus sales farmacéuticamente aceptables, y con composiciones que los contienen. (Ver Formula) La presente invención también se relaciona con un proceso para la preparación de los compuestos novedosos mencionados y de sus sales farmacéuticamente aceptables. Los compuestos de fórmula (I) son útiles en el tratamiento de diversos trastornos relacionados con los receptores 5-HT4.
MX2013014577A 2011-09-19 2012-01-05 Compuestos de heteroarilo como ligandos del receptor 5-ht4. MX337721B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3203CH2011 2011-09-19
PCT/IN2012/000011 WO2013042135A1 (en) 2011-09-19 2012-01-05 Heteroaryl compounds as 5-ht4 receptor ligands

Publications (2)

Publication Number Publication Date
MX2013014577A true MX2013014577A (es) 2014-03-31
MX337721B MX337721B (es) 2016-03-16

Family

ID=46001349

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014577A MX337721B (es) 2011-09-19 2012-01-05 Compuestos de heteroarilo como ligandos del receptor 5-ht4.

Country Status (26)

Country Link
US (2) US9079894B2 (es)
EP (1) EP2758394B1 (es)
JP (1) JP5714729B2 (es)
KR (1) KR101551481B1 (es)
CN (1) CN103380131B (es)
AP (1) AP3307A (es)
AU (1) AU2012311057B2 (es)
BR (1) BR112014001083B8 (es)
CA (1) CA2823548C (es)
CY (1) CY1116173T1 (es)
DK (1) DK2758394T3 (es)
EA (1) EA022374B1 (es)
ES (1) ES2531885T3 (es)
HK (1) HK1187340A1 (es)
HR (1) HRP20150229T1 (es)
IL (1) IL231305A0 (es)
ME (1) ME02107B (es)
MX (1) MX337721B (es)
PL (1) PL2758394T3 (es)
PT (1) PT2758394E (es)
RS (1) RS53940B1 (es)
SG (1) SG2014003560A (es)
SI (1) SI2758394T1 (es)
SM (1) SMT201500087B (es)
WO (1) WO2013042135A1 (es)
ZA (1) ZA201309100B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833507A1 (en) * 2011-06-07 2012-12-13 Dainippon Sumitomo Pharma Co., Ltd. Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
CN105120851A (zh) * 2013-04-05 2015-12-02 Abc生物科学公司 用于医疗用途，具体为用于治疗与氧化应激相关的疾病或者炎症和用于保存或者洗涤器官的barettin及其衍生物
EA029951B1 (ru) 2013-12-16 2018-06-29 Сувен Лайф Сайенсиз Лимитед Соединения индазола в качестве агонистов 5-ht-рецептора
DK3180333T3 (da) * 2014-08-16 2020-09-28 Suven Life Sciences Ltd Fremgangsmåde til storstilet fremstilling af 1-isopropyl-3-{5- [1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1h-indazoloxalat
KR101966576B1 (ko) * 2015-02-13 2019-04-05 수벤 라이프 사이언시스 리미티드 5-ht4 수용체 작용제로서 아미드 화합물
CN107540568A (zh) * 2017-08-25 2018-01-05 许昌恒生制药有限公司 一种乙氧酰胺苯甲酯的制备方法
BR112021007365A2 (pt) * 2018-10-18 2021-07-20 Suven Life Sciences Limited novos usos de um agonista do receptor 5-ht4
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
CN110746450A (zh) * 2019-09-17 2020-02-04 济南康和医药科技有限公司 一种贝前列素钠关键中间体的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492919A (en) * 1991-08-03 1996-02-20 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
TW360653B (en) * 1995-03-01 1999-06-11 Janssen Pharmaceutica Nv A oxadiazole compound having colon motility stimulating properties, its preparation process and its pharmaceutical composition
EE03487B1 (et) * 1995-11-09 2001-08-15 Synthlabo 5-fenüül-3-(piperidin-4-üül)-1,3,4-oksadiasol-2(3H)-ooni derivaadid kasutamiseks 5-HT4 - või H3- retseptorite ligandidena
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
EP1689742B1 (en) 2003-11-24 2010-03-17 Pfizer, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
DK1856110T3 (da) * 2005-02-22 2011-08-15 Pfizer Oxyindol derivater som 5HT4-receptor agonister
EP1856114B1 (en) 2005-02-25 2014-08-20 Pfizer Inc. Benzisoxazole derivatives
JP5075818B2 (ja) 2005-07-22 2012-11-21 ファイザー株式会社 ５ｈｔ４受容体アゴニストとしてのインダゾールカルボキサミド誘導体
KR101121240B1 (ko) * 2005-12-23 2012-06-12 에프. 호프만-라 로슈 아게 아릴-아이속사졸-4-일-옥사다이아졸 유도체
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
WO2010102958A1 (en) * 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases

Also Published As

Publication number Publication date
US9079894B2 (en) 2015-07-14
JP5714729B2 (ja) 2015-05-07
EP2758394A1 (en) 2014-07-30
BR112014001083A2 (pt) 2019-10-01
EA201391056A1 (ru) 2013-12-30
EP2758394B1 (en) 2015-02-18
US20150283125A1 (en) 2015-10-08
JP2014509320A (ja) 2014-04-17
ZA201309100B (en) 2014-08-27
AP3307A (en) 2015-06-30
SG2014003560A (en) 2014-11-27
BR112014001083B1 (pt) 2022-02-01
BR112014001083B8 (pt) 2022-06-14
US9636335B2 (en) 2017-05-02
IL231305A0 (en) 2014-04-30
SMT201500087B (it) 2015-05-05
RS53940B1 (en) 2015-08-31
CA2823548A1 (en) 2013-03-28
PT2758394E (pt) 2015-04-22
WO2013042135A8 (en) 2013-08-15
AP2013007301A0 (en) 2013-12-31
US20140187581A1 (en) 2014-07-03
MX337721B (es) 2016-03-16
CN103380131A (zh) 2013-10-30
CA2823548C (en) 2015-10-27
AU2012311057A1 (en) 2013-08-01
KR20130109228A (ko) 2013-10-07
HRP20150229T1 (hr) 2015-04-10
SI2758394T1 (sl) 2015-05-29
AU2012311057B2 (en) 2015-09-17
CN103380131B (zh) 2015-12-02
WO2013042135A1 (en) 2013-03-28
HK1187340A1 (zh) 2014-04-04
PL2758394T3 (pl) 2015-08-31
NZ619776A (en) 2015-04-24
DK2758394T3 (en) 2015-04-20
CY1116173T1 (el) 2017-02-08
ES2531885T3 (es) 2015-03-20
ME02107B (me) 2015-10-20
KR101551481B1 (ko) 2015-09-08
BR112014001083A8 (pt) 2021-08-24
EA022374B1 (ru) 2015-12-30

Similar Documents

Publication Publication Date Title
MX2013014577A (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
MX339858B (es) Compuestos novedosos como ligandos del receptor h3 de la histamina.
PH12015500376B1 (en) Novel bicyclic pyridinones
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2013013950A (es) Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina.
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
MX360330B (es) Regimen de administracion para nitrocatecoles.
MX362858B (es) Proceso para la preparacion de pemetrexed y sal de lisina del mismo.
MX2012002608A (es) Compuesto 1,2-dihidro -2-oxoquinolona como ligandos del receptor 5ht4.
MX2013003202A (es) Inhibidores de oxadiazol de la produccion de leucotrienos.
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
MX2012007783A (es) Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
EA201390327A1 (ru) Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов
WO2013048949A3 (en) Selective nr2b antagonists
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX337106B (es) Antagonistas no competitivos de receptores nicotinicos.
EA201590413A1 (ru) Соединения акриламида в качестве лигандов h-рецептора гистамина
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.
MX2015012350A (es) Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5ht4.
TN2013000441A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
MX2013007952A (es) Antagonistas no competitivos de receptores nicotinicos.
TN2013000122A1 (en) Oxadiazole inhibitors of leukotriene production
UA108500C2 (ru) Неконкурентные антагонисты никотиновых рецепторов

Legal Events

Date Code Title Description
FG Grant or registration